Dafinchi AI

Healthcare

Adjusted EBITDA loss improved by $10 million to a loss of $51.9 million in Q2 2025.
Biopharma business delivered record revenue of $56 million, up 28% year-over-year.
Cash, cash equivalents and restricted cash totaled approximately $735 million at quarter end.
Free cash flow burn reduced to $65.9 million from $99.1 million in the prior year period.
Guardant360 Liquid volume growth accelerated for the fourth consecutive quarter, exceeding 20% growth in Q2.
Guardant360 Tissue ASP reached approximately $2,000 in Q2, achieving the 2028 target three years early.
Non-GAAP gross profit increased 44% year-over-year to $153.8 million with a gross margin of 66%, up from 60% in Q2 2024.
Non-GAAP operating expenses increased 20% to $215.3 million, with sales and marketing expenses up 45% due to screening commercial build-out.
Oncology revenue increased 22% to $159 million with oncology volumes up 30% year-over-year to approximately 64,000 tests.
Q2 revenue grew 31% year-over-year to $232 million with strong performance across oncology, screening, biopharma and data businesses.
Shield testing revenue was $14.8 million in Q2 from approximately 16,000 tests with non-GAAP gross margin improving to 48%.

IRTC

Healthcare

Adjusted EBITDA margin improved by 500 basis points to 8.4%, compared to 3.4% in Q2 2024, reflecting operational efficiencies and volume leverage.
Adjusted net loss improved to $10.2 million or $0.32 per share from $18.8 million or $0.61 per share in Q2 2024.
Adjusted operating expenses increased 16% year-over-year to $145.2 million due to remediation activities, global volume growth support, and investments in innovation and commercial initiatives.
Expanded access to Zio services as an in-network benefit to over 10 million additional patients in the U.S.
Gross margin was 71.2%, ahead of expectations, benefiting from volume leverage and operational efficiencies despite higher costs from increased Zio AT mix.
iRhythm reported Q2 2025 revenue of $186.7 million, up 26.1% year-over-year, driven by growth in core long-term continuous monitoring and Zio AT product lines.
New store growth accounted for approximately 68% of year-over-year volume growth, with home enrollment for Zio Services at about 23% of volume in the U.S.

NBIX

Healthcare

CRENESSITY sales grew from $15 million in Q1 2025 to $53 million in Q2 2025, reflecting strong early adoption.
Gross to net was impacted by contracting and co-pay assistance programs, particularly for INGREZZA.
INGREZZA delivered $624 million in Q2 sales, with 15% sequential growth and 8% year-over-year growth.
INGREZZA saw record new patient starts and total prescriptions, with prescription market share gains in the first half of 2025.
Neurocrine Biosciences reported $682 million in net product sales during Q2 2025, representing 17% year-over-year growth.
Over 75% of CRENESSITY dispensed prescriptions were reimbursed in Q2 2025.
There was a $5 million inventory build in the quarter reflecting channel growth for CRENESSITY.

Earnings Feed